Keyword Search

By downloading an article in PDF format, you are agreeing to follow our Article Policy.


Use the KEYWORD search located in the top left column to look for keywords, authors, and titles. If you still can't find what you're looking for, please This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

Protein Recovery from Tobacco Extract by Non-Chromatographic Methods

by Chenming (Mike) Zhang, PhD
Volume 5, Issue 1 (Spring 2006)

For more than a decade, transgenic plants have been investigated as alternatives to microbial, mammalian cell, and transgenic animal systems for recombinant protein production. The main advantages of using plants as "bioreactors" are that the cost of upstream production (i.e. biomass creation) is low; plants do not carry viruses and other pathogens dangerous to humans such as human immunodeficiency virus (HIV), prions, hepatitis viruses and so on; and as eukaryotes, plants are capable of producing bioactive proteins. Numerous recombinant proteins have been expressed in various plant hosts, and some recombinant proteins are in various stages of clinical trials...

Citation:
Zhang C. Protein Recovery from Tobacco Extract by Non-Chromatographic Methods.
BioProcess J, 2006; 5(1): 19-23. https://doi.org/10.12665/J51.Zhang

 
Improved Expression of ADAM17 by Co-Expression of the Furin Convertase Protein Using Recombinant Baculoviruses

by Loĭc Glez, Christophe Losberger, and Thierry Battle, PhD
Volume 5, Issue 1 (Spring 2006)

The baculovirus expression vector system, which is based on infecting insect cells with recombinant Autographa californica nuclear polyhedrosis virus (AcNPV), is one of the most commonly used eukaryotic expression systems aimed at producing functionally active mammalian proteins. It offers advantages such as high-level protein expression and post-translational processing capabilities that are extremely important to the biological activity of certain proteins. This system utilizes a strong promoter of the very late gene, polyhedrin, to drive heterologous protein pverexpression. Nevertheless, in order to generate milligram amounts of recombinant proteins, cell culture often needs to be scaled up to as much as 25 liters....

Citation:
Glez L, Losberger C, Battle T. Improved Expression of ADAM17 by Co-Expression of the Furin Convertase Protein Using Recombinant Baculoviruses.
BioProcess J, 2006; 5(1): 24-28. https://doi.org/10.12665/J51.Glez

 
The Quest for a Generic IgG Purification Process

by Pete Gagnon
Volume 5, Issue 1 (Spring 2006)

The outstanding success and safet record of first generation monoclonal products has created an immense increase in the number of product candidates that need to be evaluated clinically. The concept of platform purification has emerged in response to this need. A platform is a semigeneric, multistep purification procedure that can be applied to a wide range of monoclonal antibodies without extensive mehtod-scouting and optimization. This approach can substantially accelerate process development and hasten inception of clinical trials...

Citation:
Gagnon P. The Quest for a Generic IgG Purification Process.
BioProcess J, 2006; 5(1): 31-36. https://doi.org/10.12665/J51.Gagnon

 
Development of a Production and Purification Method for Type 5 Adenovirus

by Scott Jendrek, Denise Ekstrom, PhD, Daniel Stoughton, PhD, Sawako Ishikawa, Dexter Poon, PhD, Wei Cheng, Steve Giardina, PhD, and David Mallard
Volume 5, Issue 1 (Spring 2006)

The number of viral vectors designed for gene therapy applications in the cGMP pipeline is staggering. Similar in scope to the flurry of recombinant protein products of the 1980s and the monoclonal antibodies (MAbs) of the 1990s, viral vector-based products are surging from research labs and universities into contract manufacturing organizations (CMOs), ultimately destined for use in clinical trials. Unlike recombinant proteins and MAbs, both of which sometimes require grams of vialed final product to start Phase I studies, the amount of material required to move a viral vector-based product into clinical trials can be minute in comparison. Of all the viral vectors currently in clinical trials, more than 25% are based on adenovirus...

Citation:
Jendrek S, Ekstrom D, Stoughton D, Ishikawa S, Poon D, Cheng W, Giardina S, Mallard D. Development of a Production and Purification Method for Type 5 Adenovirus.
BioProcess J, 2006; 5(1): 37-42. https://doi.org/10.12665/J51.Jendrek

 
Integrity Testing of Normal Flow Parvovirus Filters Using Air-Liquid Based Tests

by Glen Bolton, Jason Cormier, Mani Krishnan, John Lewnard, and Herbert Lutz
Volume 5, Issue 1 (Spring 2006)

Manufacturers must demonstrate, with a very high degree of assurance, that biopharmaceutical products derived from mammalian cells or from human plasma are safe and free of viral contamination. Viruses can be physically removed from most proteins using filtration. Often air diffusion is used as a nondestructive test to ensure that a process filter is installed properly and free of defects that can compromise virus retention. In this article, theoretical models were used to relate air an liquid flow rates through integral and defective filters. The effect of defect diameter and defect density on the virus retentive ability of a filter was also modeled...

Citation:
Bolton G, Cormier J, Krishnan M, Lewnard J, Lutz H. Integrity Testing of Normal Flow Parvovirus Filters Using Air-Liquid Based Tests.
BioProcess J, 2006; 5(1): 52-57. https://doi.org/10.12665/J51.Bolton

 
Effects of Mutation in Protease on the Production of Human Immunodeficiency Virus Type-1 Virus-Like Particles

by Bin Li, James Smith, PhD, Salvatore T. Butera, DVM, PhD, and Dennis L. Ellenberger, PhD
Volume 5, Issue 1 (Spring 2006)

As human immunodeficiency virus type-1 (HIV-1) continues to spread around the world, scientists are actively pursuing effective vaccines against the infectious disease that results in AIDS. A number of vaccine designs have been developed, including plasmid DNA constructs encoding HIV proteins. One advantage of DNA vaccination is that after the uptake of the plasmid by the host cells, the encoded antigens are expressed in the native conformation and allow authentic immunological processing of the antigen. Another advantage of DNA vaccines is that they can be repeatedly administered without vector-directed immunity limiting the efficacy of the boost. DNA vaccines alone can induce both humoral and cellular immune responses and provide modest protection against disease progression in the preclinical, nonhuman primate model when challenged with simian immunodeficiency virus (SIV)...

Citation:
Li B, Smith J, Butera ST, Ellenberger DL. Effects of Mutation in Protease on the Production of Human Immunodeficiency Virus Type-1 Virus-Like Particles.
BioProcess J, 2006; 5(1): 43-51. https://doi.org/10.12665/J51.Butera

 
<< Start < Prev 41 42 43 44 45 46 47 48 49 50 Next > End >>

Endorsed Events
Please update your Flash Player to view content.
Please update your Flash Player to view content.